CN110234403A - 作为sting激动剂的环状二核苷酸 - Google Patents

作为sting激动剂的环状二核苷酸 Download PDF

Info

Publication number
CN110234403A
CN110234403A CN201880009026.9A CN201880009026A CN110234403A CN 110234403 A CN110234403 A CN 110234403A CN 201880009026 A CN201880009026 A CN 201880009026A CN 110234403 A CN110234403 A CN 110234403A
Authority
CN
China
Prior art keywords
compound
mmol
added
mixture
give
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880009026.9A
Other languages
English (en)
Chinese (zh)
Inventor
S.伊曼纽尔
M.里克特
P.J.康诺利
J.P.爱德华兹
王广义
S.K.塔提孔达
L.贝高曼
钟明宏
G.比尼昂
W.舍彭斯
M.维勒沃耶
J.W.J.F.图林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Ortho Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc filed Critical Centocor Ortho Biotech Inc
Publication of CN110234403A publication Critical patent/CN110234403A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CN201880009026.9A 2017-01-27 2018-01-26 作为sting激动剂的环状二核苷酸 Pending CN110234403A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762451301P 2017-01-27 2017-01-27
US201762451351P 2017-01-27 2017-01-27
US62/451301 2017-01-27
US62/451351 2017-01-27
US201762454135P 2017-02-03 2017-02-03
US62/454135 2017-02-03
PCT/IB2018/050498 WO2018138685A2 (en) 2017-01-27 2018-01-26 Cyclic dinucleotides as sting agonists

Publications (1)

Publication Number Publication Date
CN110234403A true CN110234403A (zh) 2019-09-13

Family

ID=61187610

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880009026.9A Pending CN110234403A (zh) 2017-01-27 2018-01-26 作为sting激动剂的环状二核苷酸

Country Status (7)

Country Link
US (2) US11492367B2 (cg-RX-API-DMAC7.html)
EP (1) EP3573718B1 (cg-RX-API-DMAC7.html)
JP (2) JP7275031B2 (cg-RX-API-DMAC7.html)
CN (1) CN110234403A (cg-RX-API-DMAC7.html)
AU (1) AU2018212788A1 (cg-RX-API-DMAC7.html)
ES (1) ES2924186T3 (cg-RX-API-DMAC7.html)
WO (1) WO2018138685A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112321589A (zh) * 2020-02-18 2021-02-05 山东科巢生物制药有限公司 一种抗病毒药物瑞德西韦及其中间体的合成方法

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912074PA (en) 2016-03-18 2020-02-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
RU2020112502A (ru) * 2017-08-30 2021-10-01 Бейцзин Сюаньи Фармасайенсиз Ко., Лтд. Циклические динуклеотиды в качестве стимулятора модуляторов генов интерферона
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
MX2020004858A (es) 2017-11-10 2020-10-01 Takeda Pharmaceuticals Co Compuestos moduladores de sting y metodos de elaboracion y uso.
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
EP3728282B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US10519187B2 (en) * 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
MX2021002764A (es) 2018-09-12 2021-05-12 Silverback Therapeutics Inc Composiciones para el tratamiento de enfermedades con conjugados inmunoestimuladores.
US11161864B2 (en) 2018-10-29 2021-11-02 Venenum Biodesign, LLC Sting agonists
US11110106B2 (en) 2018-10-29 2021-09-07 Venenum Biodesign, LLC Sting agonists for treating bladder cancer and solid tumors
US11293061B2 (en) 2018-12-26 2022-04-05 Illumina Cambridge Limited Sequencing methods using nucleotides with 3′ AOM blocking group
WO2020178768A1 (en) * 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
EP3966222A4 (en) 2019-05-09 2023-10-04 Aligos Therapeutics, Inc. MODIFIED CYCLIC DI-NUCLEOSIDE COMPOUNDS AS STING MODULATORS
CA3145889A1 (en) 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
CA3151322A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
BR112022026056A2 (pt) 2020-06-22 2023-03-07 Illumina Cambridge Ltd Nucleosídeos e nucleotídeos com grupo bloqueador 3? acetal
JP2023532304A (ja) 2020-07-01 2023-07-27 エーアールエス ファーマシューティカルズ オペレーションズ，インク． 抗ａｓｇｒ１抗体コンジュゲートおよびその使用
EP4192506A1 (en) 2020-08-07 2023-06-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
MX2023005381A (es) 2020-11-09 2023-05-23 Takeda Pharmaceuticals Co Conjugados de anticuerpo y farmaco.
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
WO2023023527A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014179335A1 (en) * 2013-04-29 2014-11-06 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
US20140341976A1 (en) * 2013-05-18 2014-11-20 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" -dependent signalling
WO2014189806A1 (en) * 2013-05-18 2014-11-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
WO2014189805A1 (en) * 2013-05-18 2014-11-27 Auro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
CN105377867A (zh) * 2013-05-03 2016-03-02 加利福尼亚大学董事会 I型干扰素的环状二核苷酸诱导
WO2016120305A1 (en) * 2015-01-29 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Cyclic dinucleotides useful for the treatment of inter alia cancer
WO2017027646A1 (en) * 2015-08-13 2017-02-16 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
WO2017075477A1 (en) * 2015-10-28 2017-05-04 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
WO2017093933A1 (en) * 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
WO2017161349A1 (en) * 2016-03-18 2017-09-21 Immune Sensor, Llc Cyclic di-nucleotide compounds and methods of use
CN110291096A (zh) * 2016-11-25 2019-09-27 詹森生物科技公司 环状二核苷酸作为sting激动剂
CN110325543A (zh) * 2016-12-01 2019-10-11 武田药品工业有限公司 作为sting(干扰素基因刺激因子)激动剂的环状二核苷酸

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
EP1368458A2 (en) 2001-02-26 2003-12-10 Pharma Pacific Pty. Ltd. Interferon-alpha induced gene
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
TWI605828B (zh) 2008-12-09 2017-11-21 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
JP6238459B2 (ja) 2011-08-01 2017-11-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
WO2013179289A1 (en) 2012-05-31 2013-12-05 Bio-Lab Ltd. Pyrazolotriazolyl nucleoside analogues and oligonucleotides comprising them
EP3071209A4 (en) 2013-11-19 2017-08-16 The University of Chicago Use of sting agonist as cancer treatment
EP3152217B1 (en) 2014-06-04 2018-08-01 GlaxoSmithKline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
WO2017186711A1 (en) * 2016-04-25 2017-11-02 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
WO2018119117A1 (en) * 2016-12-22 2018-06-28 The Regents Of The University Of California Methods of producing cyclic dinucleotides

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014179335A1 (en) * 2013-04-29 2014-11-06 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
CN105377867A (zh) * 2013-05-03 2016-03-02 加利福尼亚大学董事会 I型干扰素的环状二核苷酸诱导
US20140341976A1 (en) * 2013-05-18 2014-11-20 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" -dependent signalling
WO2014189806A1 (en) * 2013-05-18 2014-11-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
WO2014189805A1 (en) * 2013-05-18 2014-11-27 Auro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
WO2016120305A1 (en) * 2015-01-29 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Cyclic dinucleotides useful for the treatment of inter alia cancer
WO2017027646A1 (en) * 2015-08-13 2017-02-16 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
WO2017075477A1 (en) * 2015-10-28 2017-05-04 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
WO2017093933A1 (en) * 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
WO2017161349A1 (en) * 2016-03-18 2017-09-21 Immune Sensor, Llc Cyclic di-nucleotide compounds and methods of use
CN110291096A (zh) * 2016-11-25 2019-09-27 詹森生物科技公司 环状二核苷酸作为sting激动剂
CN110325543A (zh) * 2016-12-01 2019-10-11 武田药品工业有限公司 作为sting(干扰素基因刺激因子)激动剂的环状二核苷酸

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACT SERVICE, COLUMBUS, OHIO, US: "STN Registry", 《STN REGISTRY》, pages 1 - 4 *
THIERRY LIOUX ET AL.: "Design, synthesis, and biological evaluation of novel cyclic adenosine-inosine monophosphate (cAIMP) analogs that activate stimulator of interferon genes (STING)", 《J. MED. CHEM.》, pages 3 *
沈国栋等: "固有免疫信号分子STING研究进展", 《免疫学杂志》, vol. 29, no. 7, pages 624 - 627 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112321589A (zh) * 2020-02-18 2021-02-05 山东科巢生物制药有限公司 一种抗病毒药物瑞德西韦及其中间体的合成方法
CN112321589B (zh) * 2020-02-18 2022-05-03 山东科巢生物制药有限公司 一种抗病毒药物瑞德西韦及其中间体的合成方法

Also Published As

Publication number Publication date
US20190375782A1 (en) 2019-12-12
AU2018212788A1 (en) 2019-07-25
ES2924186T3 (es) 2022-10-05
US11492367B2 (en) 2022-11-08
WO2018138685A2 (en) 2018-08-02
JP2020505405A (ja) 2020-02-20
EP3573718A2 (en) 2019-12-04
US20230146410A1 (en) 2023-05-11
JP7275031B2 (ja) 2023-05-17
WO2018138685A3 (en) 2018-10-04
EP3573718B1 (en) 2022-06-01
JP2022180398A (ja) 2022-12-06

Similar Documents

Publication Publication Date Title
CN110234403A (zh) 作为sting激动剂的环状二核苷酸
CN110291096A (zh) 环状二核苷酸作为sting激动剂
AU2018212787B2 (en) Cyclic dinucleotides as sting agonists
CN111712509A (zh) 作为sting激动剂的环状二核苷酸
CN112424212A (zh) 作为sting激动剂的环状二核苷酸
HK40014582A (en) Cyclic dinucleotides as sting agonists
HK40046548A (en) Cyclic dinucleotides as sting agonists
HK40014581A (en) Cyclic dinucleotides as sting agonists
HK40036615A (en) Cyclic dinucleotides as sting agonists

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40014582

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190913